The naturally occurring Arg219Leu variant of the human 5-HT1A receptor: impairment of signal transduction.
The present study in transfected HEK293 cells aimed to investigate whether the pharmacological and/or transductional properties of the naturally occurring Arg219Leu variant (VAR) in the third intracellular loop of the h5-HT1A receptor differ from those of the wild-type receptor. Binding of [3H]8-hydroxy-2-(di-n-propylamino)tetraline ([H]8-OH-DPAT) and of [35S]GTPgammaS to membranes, as well as inhibition of forskolin-stimulated [3H]cAMP formation by 5-HT receptor agonists in whole cells, were estimated. The VAR and wild-type h5-HT1A receptors were found to be expressed at virtually identical densities. The VAR and wild-type receptors did also not differ with respect to the potencies of 5-HT receptor agonists and antagonists in inhibiting [3H]8-OH-DPAT binding. The ability of 5-HT to stimulate [35S]GTPgammaS binding (a measure of G protein coupling) to the VAR receptor and of the agonists 5-HT, buspirone and urapidil to inhibit forskolin-stimulated cAMP accumulation in HEK293 cells expressing the VAR receptor was decreased by 60-90%. In conclusion, the Arg219Leu variation of the human 5-HT1A receptor does not change the binding properties, but is associated with a drastic impairment of signal transduction. In patients carrying this variation, disturbances of 5-HT1A receptor-mediated functions and diminished responses to drugs acting via this receptor may occur.